Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

被引:155
作者
Levine, S [1 ]
Hernandez, D [1 ]
Yamanaka, G [1 ]
Zhang, S [1 ]
Rose, R [1 ]
Weinheimer, S [1 ]
Colonno, RJ [1 ]
机构
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA
关键词
D O I
10.1128/AAC.46.8.2525-2532.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Entecavir (ETV) is a potent and selective inhibitor of hepatitis B virus (HBV) replication in vitro and in vivo that is currently in clinical trials for the treatment of chronic HBV infections. A major limitation of the current HBV antiviral therapy, lamivudine (3TC), is the emergence of drug-resistant HBV in a majority of treated patients due to specific mutations in the nucleotide binding site of HBV DNA polymerase (HBV Pol). To determine the effects of 3TC resistance mutations on inhibition by ETV triphosphate (ETV-TP), a series of in vitro studies were performed. The inhibition of wild-type and 3TC-resistant HBV Pol by ETV-TP was measured using recombinant HBV nucleocapsids, and compared to that of 3TC-TP. These enzyme inhibition studies demonstrated that ETV-TP is a highly potent inhibitor of wild-type HBV Pol and is 100- to 300-fold more potent than 3TC-TP against 3TC-resistant HBV Pol. Cell culture assays were used to gauge the potential for antiviral cross-resistance of 3TC-resistant mutants to ETV. Results demonstrated that ETV inhibited the replication of 3TC-resistant HBV, but 20- to 30-fold higher concentrations were required. To gain further perspective regarding the potential therapeutic use of ETV, its phosphorylation was examined in hepatoma cells treated with extracellular concentrations representative of drug levels in plasma in ETV-treated patients. At these concentrations, intracellular ETV-TP accumulated to levels expected to inhibit the enzyme activity of both wild-type and 3TC-resistant HBV Pol. These findings are predictive of potent antiviral activity of ETV against both wild-type and 3TC-resistant HBV.
引用
收藏
页码:2525 / 2532
页数:8
相关论文
共 32 条
[11]   MUTATIONS IN THE EPSILON-SEQUENCES OF HUMAN HEPATITIS-B VIRUS AFFECT BOTH RNA ENCAPSIDATION AND REVERSE TRANSCRIPTION [J].
FALLOWS, DA ;
GOFF, SP .
JOURNAL OF VIROLOGY, 1995, 69 (05) :3067-3073
[12]   Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus [J].
Fu, L ;
Cheng, YC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) :3402-3407
[13]   Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection [J].
Genovesi, EV ;
Lamb, L ;
Medina, I ;
Taylor, D ;
Seifer, M ;
Innaimo, S ;
Colonno, RJ ;
Standring, DN ;
Clark, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (12) :3209-3217
[14]   Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B [J].
Hussain, M ;
Lok, ASF .
JOURNAL OF VIRAL HEPATITIS, 1999, 6 (03) :183-194
[15]   Identification of EMS-200475 as a potent and selective inhibitor of hepatitis B virus [J].
Innaimo, SF ;
Seifer, M ;
Bisacchi, GS ;
Strandring, DN ;
Zahler, R ;
Colonno, RJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1444-1448
[16]   Clinical pharmacokinetics of lamivudine [J].
Johnson, MA ;
Moore, KHP ;
Yuen, GJ ;
Bye, A ;
Pakes, GE .
CLINICAL PHARMACOKINETICS, 1999, 36 (01) :41-66
[17]  
Kewn S, 2000, BRIT J CLIN PHARMACO, V50, P597
[19]   The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2′-deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA [J].
Ladner, SK ;
Miller, TJ ;
King, RW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2128-2131
[20]   A phase II study of entecavir vs lamivudine in adults with chronic hepatitis B [J].
Lai, C ;
Rosmawati, M ;
Lao, J ;
Van Vlierberghe, H ;
Anderson, F ;
Thomas, N ;
De Hertogh, D .
JOURNAL OF HEPATOLOGY, 2001, 34 :24-24